Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: Potentiation of morphine anti-allodynic activity by NOP receptor antagonists

European Journal of Pharmacology

Volumn 610, Issue 1-3, 2009, Pages 49-54

  Khroyan, Taline V ^a   Polgar, Willma E ^a   Orduna, Juan ^a   Jiang, Faming ^a   Olsen, Cris ^a   Toll, Lawrence ^a   Zaveri, Nurulain T ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Chronic constriction injury; Chronic pain; N OFQ; Neuropathy; NOP; NOP antagonist

Indexed keywords

1 (1 BICYCLO[3.3.1]NONAN 9 YL)PIPERIDIN 4 YL)INDOLIN 2 ONE; 1 (1 CYCLOOCTYLMETHYLPIPERIDIN 4 YL)INDOLIN 2 ONE; 1 (1 CYCLOOCTYLPIPERIDIN 4 YL)INDOLIN 2 ONE; 1 CYCLOOCTYLMETHYL 4 HYDROXY 4 (3 TRIFLUOROMETHYLPHENYL)PIPERIDINE; LIGAND; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALOXONE; NOCICEPTIN RECEPTOR AGONIST; NOCICEPTIN RECEPTOR ANTAGONIST; SR 14148; SR 14150; SR 16430; SR 16435; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; MALE; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT;

ANALGESICS, OPIOID; ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; LIGANDS; MALE; MONONEUROPATHIES; MORPHINE; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; SCIATIC NERVE;

EID: 67349253062     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.019     Document Type: Article

References (41)

1. Ballantyne J.C., and Mao J. Opioid therapy for chronic pain. N. Engl. J. Med. 349 (2003) 1943-1953
2. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
3. Bian D., Ossipov M.H., Ibrahim M., Raffa R.B., Tallarida R.J., Malan Jr. T.P., Lai J., and Porreca F. Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum. Brain Res. 831 (1999) 55-63
4. Bloms-Funke P., Gillen C., Schuettler A.J., and Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21 (2000) 1141-1146
5. Briscini L., Corradini L., Ongini E., and Bertorelli R. Up-regulation of ORL-1 receptors in spinal tissue of allodynic rats after sciatic nerve injury. Eur. J. Pharmacol. 447 (2002) 59-65
6. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53 (1994) 55-63
7. Christoph T., Kogel B., Schiene K., Meen M., De Vry J., and Friderichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur. J. Pharmacol. 507 (2005) 87-98
8. Corradini L., Briscini L., Ongini E., and Bertorelli R. The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats. Brain Res. 905 (2001) 127-133
9. Coudore-Civiale M.A., Courteix C., Boucher M., Meen M., Fialip J., Eschalier A., and Ardid D. Potentiation of morphine and clomipramine analgesia by cholecystokinin-B antagonist CI-988 in diabetic rats. Neurosci. Lett. 286 (2000) 37-40
10. Coudore-Civiale M.A., Courteix C., Fialip J., Boucher M., and Eschalier A. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats. Pain 88 (2000) 15-22
11. Courteix C., Coudore-Civiale M.A., Privat A.M., Pelissier T., Eschalier A., and Fialip J. Evidence for an exclusive antinociceptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain. Pain 110 (2004) 236-245
12. Dooley C.T., Spaeth C.G., Berzetei-Gurske I.P., Craymer K., Adapa I.D., Brandt S.R., Houghten R.A., and Toll L. Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J. Pharmacol. Exp. Ther. 283 (1997) 735-741
13. Dworkin R.H., O, Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., Kalso E.A., Loeser J.D., Miaskowski C., Nurmikko T.J., Portenoy R.K., Rice A.S., Stacey B.R., Treede R.D., Turk D.C., and Wallace M.S. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132 (2007) 237-251
14. Hao J.X., Xu I.S., Wiesenfeld-Hallin Z., and Xu X.J. Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Pain 76 (1998) 385-393
15. Heinricher M.M. Nociceptin/orphanin FQ: pain, stress and neural circuits. Life Sci. 77 (2005) 3127-3132
16. Heit H.A., and Gourlay D.L. Buprenorphine: new tricks with an old molecule for pain management. Clin. J. Pain 24 (2008) 93-97
17. Huang P., Kehner G.B., Cowan A., and Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 297 (2001) 688-695
18. Khroyan T.V., Polgar W.E., Orduna J., Zaveri N.T., Judd A.K., Tuttle D.J., Sanchez A., and Toll L. Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodents. Eur. J. Pharmacol. 560 (2007) 29-35
19. Khroyan T.V., Zaveri N.T., Polgar W.E., Orduna J., Olsen C., Jiang F., and Toll L. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J. Pharmacol. Exp. Ther. 320 (2007) 934-943
20. Lutfy K., Eitan S., Bryant C.D., Yang Y.C., Saliminejad N., Walwyn W., Kieffer B.L., Takeshima H., Carroll F.I., Maidment N.T., and Evans C.J. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J. Neurosci. 23 (2003) 10331-10337
21. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
22. Mika J., Schafer M.K., Obara I., Weihe E., and Przewlocka B. Morphine and endomorphin-1 differently influence pronociceptin/orphanin FQ system in neuropathic rats. Pharmacol. Biochem. Behav. 78 (2004) 171-178
23. Mogil J.S., Grisel J.E., Reinscheid R.K., Civelli O., Belknap J.K., and Grandy D.K. Orphanin FQ is a functional anti-opioid peptide. Neuroscience 75 (1996) 333-337
24. Nichols M.L., Lopez Y., Ossipov M.H., Bian D., and Porreca F. Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy. Pain 69 (1997) 317-322
25. Obara I., Przewlocki R., and Przewlocka B. Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat. Pain 116 (2005) 17-25
26. Ossipov M.H., Lopez Y., Nichols M.L., Bian D., and Porreca F. Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci. Lett. 199 (1995) 83-86
27. Przewlocki R., and Przewlocka B. Opioids in chronic pain. Eur. J. Pharmacol. 429 (2001) 79-91
28. Przewlocki R., and Przewlocka B. Opioids in neuropathic pain. Curr. Pharm. Des. 11 (2005) 3013-3025
29. Raffaeli W., Samolsky Dekel B.G., Landuzzi D., Caminiti A., Righetti D., Balestri M., Montanari F., Romualdi P., and Candeletti S. Nociceptin levels in the cerebrospinal fluid of chronic pain patients with or without intrathecal administration of morphine. J. Pain Symptom Mgmt. 32 (2006) 372-377
30. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F.J., and Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
31. Spagnolo B., Calo G., Polgar W.E., Jiang F., Olsen C.M., Berzetei-Gurske I., Khroyan T.V., Husbands S.M., Lewis J.W., Toll L., and Zaveri N.T. Activities of mixed NOP and mu-opioid receptor ligands. Br. J. Pharmacol. 153 (2007) 609-619
32. Sun R.Q., Wang Y., Zhao C.S., Chang J.K., and Han J.S. Changes in brain content of nociceptin/orphanin FQ and endomorphin 2 in a rat model of neuropathic pain. Neurosci. Lett. 311 (2001) 13-16
33. Suyama H., Kawamoto M., Gaus S., and Yuge O. Effect of JTC-801 (nociceptin antagonist) on neuropathic pain in a rat model. Neurosci. Lett. 351 (2003) 133-136
34. Tian J.H., Xu W., Fang Y., Mogil J.S., Grisel J.E., Grandy D.K., and Han J.S. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br. J. Pharmacol. 120 (1997) 676-680
35. Xu X.J., Hao J.X., and Wiesenfeld-Hallin Z. Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. Neuroreport 7 (1996) 2092-2094
36. Yamamoto T., Nozaki-Taguchi N., and Kimura S. Analgesic effect of intrathecally administered nociceptin, an opioid receptor-like1 receptor agonist, in the rat formalin test. Neuroscience 81 (1997) 249-254
37. Yamamoto T., Nozaki-Taguchi N., and Kimura S. Effects of intrathecally administered nociceptin, an opioid receptor-like1 (ORL1) receptor agonist, on the thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat. Neurosci. Lett. 224 (1997) 107-110
38. Yamamoto T., Shono K., and Tanabe S. Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J. Pharmacol. Exp. Ther. 318 (2006) 206-213
39. Zaratin P.F., Petrone G., Sbacchi M., Garnier M., Fossati C., Petrillo P., Ronzoni S., Giardina G.A., and Scheideler M.A. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8, 9- tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J. Pharmacol. Exp. Ther. 308 (2004) 454-461
40. Zaveri N.T., Jiang F., Olsen C.M., Deschamps J.R., Parrish D., Polgar W., and Toll L. A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor. J. Med. Chem. 47 (2004) 2973-2976
41. Zeilhofer H.U., and Calo G. Nociceptin/orphanin FQ and its receptor-potential targets for pain therapy?. J. Pharmacol. Exp. Ther. 306 (2003) 423-429